MAIA Biotechnology (MAIA) Cash from Operations (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Cash from Operations for 6 consecutive years, with -$6.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 63.23% year-over-year to -$6.8 million in Q2 2026; TTM through Jun 2026 was -$22.6 million, a 43.1% decrease from a year earlier, with the FY2025 full-year figure at -$18.8 million, down 20.0% from the prior year.
• Cash from Operations was -$6.8 million for Q2 2026 at MAIA Biotechnology, down from -$5.3 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$2.0 million in Q2 2022 and troughed at -$7.0 million in Q4 2025.
• A 5-year average of -$4.0 million and a median of -$3.7 million in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations tumbled 229.38% in 2022 and advanced 26.9% in 2023, its largest moves.
• Over 5 years, Cash from Operations stood at -$2.9 million in 2022, then sank by 35.35% to -$4.0 million in 2023, then increased by 2.11% to -$3.9 million in 2024, then plunged by 79.64% to -$7.0 million in 2025, then climbed by 3.85% to -$6.8 million in 2026.
• The last three Cash from Operations figures came in at -$6.8 million (Q2 2026), -$5.3 million (Q1 2026), and -$7.0 million (Q4 2025), per Business Quant data.